Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aponermin + Pomalidomide + Dexamethasone in RRMM
NCT06924424Active, not recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of aponermin in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response at 4 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
aponermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06924424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924424.